Previous 10 | Next 10 |
Akari Therapeutics (NASDAQ: AKTX ) announces a successful End of Phase 2 (EOP2) meeting with the FDA regarding its proposed Phase III program for the treatment of bullous pemphigoid (BP), a rare skin-blistering disorder. More news on: Akari Therapeutics, Plc, Healthcare stock...
Phase III randomized placebo-controlled study in moderate to severe bullous pemphigoid (BP) patients with a primary endpoint of complete disease remission on minimal oral corticosteroids (OCS) agreed to with the FDA. Treatment arms will be tapered to minimal OCS and an importan...
Akari Therapeutics ( AKTX +7.6% ) gains access of $30M in the securities purchase commitment from Aspire Capital as it seeks to transition its lead drug nomacopan (coversin) into phase III trials following the success of phase II . More news on: Akari Therapeutics, Plc, Healthcar...
NEW YORK and LONDON, July 01, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (“Akari” or the “Company”) (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimm...
NEW YORK and LONDON, July 01, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (“Akari” or the “Company”) (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimm...
The two most common elements in the universe are Hydrogen and stupidity .” - Harlan Ellison Today, we look at a ' Tier 4 ' biotech concern trying an unusual route to target rare and orphan diseases. A full investment analysis is provided in the paragraphs below. Company Over...
3 Penny Stocks To Watch This Week We’ve got a brand new week to find penny stocks to trade. One of the most important things you can do on the weekend is to take time to research. While all of the DD in the world can be unwound with a single piece of news, the general consensus among ...
Open pivotal study in pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) with orphan and fast track approval Preparing for pivotal study in bullous pemphigoid (BP) following recent completion of successful Phase II study Positive EMA...
NEW YORK and LONDON, May 21, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene (LTB4) systems are implicated, today...
On the heels of its meeting with the FDA, Apellis Pharmaceuticals (NASDAQ: APLS ) announces that it expects to file a marketing application in H2 seeking approval of pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease in which the immune sys...
News, Short Squeeze, Breakout and More Instantly...
Akari Therapeutics Plc Company Name:
AKTX Stock Symbol:
NASDAQ Market:
Akari Therapeutics Plc Website:
Interim CEO employment contract consists solely of equity compensation Samir R. Patel, M.D., increases ownership to 14.2% with $1.25m investment in recent private placement BOSTON and LONDON, June 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotec...
BOSTON and LONDON, June 04, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotechnology company advancing therapies for autoimmune and inflammatory diseases, today announced the successful initial closing of a private placement financing round. This transaction is ...
Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024 Samir R. Patel, M.D. Appointed Interim CEO Plan for Prioritization of Peak Bio’s ADC Cancer Therapeutic Platform Technology and Akari’s PAS-nomacopan fo...